Log in

NYSE:GSK - GlaxoSmithKline Stock Price, Forecast & News

$43.74
-0.04 (-0.09 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$43.45
Now: $43.74
$43.82
50-Day Range
$43.78
MA: $46.55
$47.89
52-Week Range
$38.43
Now: $43.74
$48.25
Volume3.23 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio18.38
Dividend YieldN/A
BetaN/A
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees95,490
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.


GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline declared a quarterly dividend on Thursday, February 6th. Investors of record on Friday, February 21st will be paid a dividend of $0.5994 per share on Thursday, April 9th. This represents a $2.40 dividend on an annualized basis and a yield of 5.48%. The ex-dividend date of this dividend is Thursday, February 20th. This is an increase from GlaxoSmithKline's previous quarterly dividend of $0.50. View GlaxoSmithKline's Dividend History.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) posted its earnings results on Wednesday, October, 30th. The pharmaceutical company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.85 by $0.10. The pharmaceutical company earned $11.57 billion during the quarter, compared to analyst estimates of $11.34 billion. View GlaxoSmithKline's Earnings History.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for GlaxoSmithKline.

What guidance has GlaxoSmithKline issued on next quarter's earnings?

GlaxoSmithKline updated its FY20 earnings guidance on Wednesday, February, 5th. The company provided EPS guidance of $1.19-1.23 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.20.

What price target have analysts set for GSK?

12 Wall Street analysts have issued 12-month target prices for GlaxoSmithKline's shares. Their forecasts range from $45.00 to $53.00. On average, they expect GlaxoSmithKline's stock price to reach $49.00 in the next year. This suggests a possible upside of 12.0% from the stock's current price. View Analyst Price Targets for GlaxoSmithKline.

What is the consensus analysts' recommendation for GlaxoSmithKline?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 3 sell ratings, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline.

Has GlaxoSmithKline been receiving favorable news coverage?

News coverage about GSK stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GlaxoSmithKline earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned media stories about the pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for GlaxoSmithKline.

Are investors shorting GlaxoSmithKline?

GlaxoSmithKline saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 6,650,000 shares, a drop of 8.5% from the January 15th total of 7,270,000 shares. Based on an average trading volume of 2,780,000 shares, the days-to-cover ratio is presently 2.4 days. Currently, 0.3% of the company's shares are short sold. View GlaxoSmithKline's Current Options Chain.

What other stocks do shareholders of GlaxoSmithKline own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Johnson & Johnson (JNJ), Bank of America (BAC), General Electric (GE) and Exxon Mobil (XOM).

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the folowing people:
  • Ms. Emma N. Walmsley, CEO & Director (Age 49)
  • Mr. Simon P. Dingemans, CFO & Exec. Director (Age 55)
  • Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 56)
  • Mr. Jack Bailey, Pres of US Pharmaceuticals
  • Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 57)

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (0.77%), Renaissance Technologies LLC (0.76%), State Street Corp (0.37%), Boston Partners (0.33%), Bank of America Corp DE (0.30%) and Hotchkis & Wiley Capital Management LLC (0.30%). View Institutional Ownership Trends for GlaxoSmithKline.

Which major investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including Bowen Hanes & Co. Inc., State Street Corp, Ariel Investments LLC, FMR LLC, Clark Estates Inc. NY, Diamond Hill Capital Management Inc., Trust Co. of Virginia VA and Kornitzer Capital Management Inc. KS. View Insider Buying and Selling for GlaxoSmithKline.

Which major investors are buying GlaxoSmithKline stock?

GSK stock was bought by a variety of institutional investors in the last quarter, including Boston Partners, Renaissance Technologies LLC, Hotchkis & Wiley Capital Management LLC, Captrust Financial Advisors, Euro Pacific Asset Management LLC, Douglas Lane & Associates LLC, Foundry Partners LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for GlaxoSmithKline.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $43.74.


MarketBeat Community Rating for GlaxoSmithKline (NYSE GSK)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  716 (Vote Outperform)
Underperform Votes:  1,065 (Vote Underperform)
Total Votes:  1,781
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Featured Article: Debt-To-Equity Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel